- Conference Call and Webcast to Follow at 5:00 p.m. EDT/ 2:00 p.m.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Apr. 26, 2016--
Exelixis, Inc. (NASDAQ: EXEL) announced today that its first quarter
2016 financial results will be released on Wednesday, May 4, 2016 after
the markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management
will host a conference call to discuss the results and provide a general
business update. The conference call will be accessible via the Internet
from the company’s website.
To access the webcast link, log onto www.exelixis.com
and proceed to the Event Calendar page under Investors & Media. Please
connect to the company’s website at least 15 minutes prior to the
conference call to ensure adequate time for any software download that
may be required to listen to the webcast. Alternatively, please call
(855) 793-2457 (domestic) or (631) 485-4921 (international) and provide
the conference call passcode 82069908 to join by phone.
A telephone replay will be available until 11:59 p.m. EDT on May 6,
2016. Access numbers for the telephone replay are: (855) 859-2056
(domestic) and (404) 537-3406 (international); the passcode is 82069908.
A webcast replay will also be archived on www.exelixis.com
for one year.
Exelixis, Inc. (Nasdaq: EXEL) is a biopharmaceutical company committed
to the discovery, development and commercialization of new medicines
with the potential to improve care and outcomes for people with cancer.
Since its founding in 1994, three medicines discovered at Exelixis have
progressed through clinical development to receive regulatory approval.
Currently, Exelixis is focused on advancing cabozantinib, an inhibitor
of multiple tyrosine kinases including MET, AXL and VEGF receptors,
which has shown clinical anti-tumor activity in more than 20 forms of
cancer and is the subject of a broad clinical development program. Two
separate formulations of cabozantinib have received regulatory approval
to treat certain forms of kidney and thyroid cancer and are marketed for
those purposes as CABOMETYX™ tablets (U.S.) and COMETRIQ®
capsules (U.S. and EU), respectively. Another Exelixis-discovered
compound, COTELLIC™ (cobimetinib), a selective inhibitor of MEK, has
been approved in major territories including the United States and
European Union, and is being evaluated for further potential indications
by Roche and Genentech (a member of the Roche Group) under a
collaboration with Exelixis. For more information on Exelixis, please
or follow @ExelixisInc on Twitter.
Exelixis, the Exelixis logo and COMETRIQ are registered U.S.
trademarks, and CABOMETYX and COTELLIC are U.S. trademarks.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160426006835/en/
Source: Exelixis, Inc.
Susan Hubbard, 650-837-8194
Relations and Corporate Communications
For Exelixis, Inc.